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OBJECTIVES This paper will describe associations between plasma natriuretic peptide levels and the severity
and symptoms of mitral regurgitation (MR).
BACKGROUND A biochemical test that assisted grading of the severity of MR and the interpretation of
symptoms would be of clinical value.
METHODS Forty-nine patients with isolated MR and left ventricular (LV) ejection fractions (EFs) of
55% underwent transthoracic echocardiography, assessment of symptoms, and measure-
ment of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and its amino-
terminal portion, N-BNP.
RESULTS The level of each natriuretic peptide rose with increasing severity of MR and with increases
in left atrial (LA) dimensions (p  0.001 for all comparisons), but no significant correlation
existed between any natriuretic peptide and the LV dimensions or EF. Natriuretic peptide
levels were higher in symptomatic MR (n  16, BNP geometric mean 16.9 [95% confidence
interval (CI) 13.3 to 21.4] pmol/l) compared with asymptomatic MR (n 33, BNP 7.1 [95%
CI 6.0 to 8.4] pmol/l, p  0.001), and higher in asymptomatic MR than in normal controls
(n  100, BNP 5.3 [95% CI 4.8 to 5.8] pmol/l, p  0.0001). These differences were similar
for N-BNP and ANP and remained statistically significant (p  0.05) after adjustment for
echocardiographic measures of LV function and severity of MR. Both the sensitivity and the
specificity for symptoms for the natriuretic peptides (area under receiver-operator character-
istic curve for BNP  0.90, N-BNP  0.89, ANP  0.89) were similar to the MR score
(0.88) and greater than for LA dimension (0.81), vena contracta width (0.82), and LV
end-systolic dimension (0.63).
CONCLUSIONS Plasma natriuretic peptides levels increase with the severity of MR and are higher in
symptomatic compared to asymptomatic patients, even when LV EF is normal. (J Am Coll
Cardiol 2003;41:2280–7) © 2003 by the American College of Cardiology Foundation
Echocardiography is the standard method used to evaluate
the severity and cause of mitral regurgitation (MR), and to
assess left ventricular (LV) systolic function (1). However, it
may be difficult to obtain an accurate quantitative assess-
ment of the severity of regurgitation (2,3). Quantitative
estimates of severity based on measurement of the regurgi-
tant fraction and the regurgitant orifice area (4) are techni-
cally demanding. Left ventricular function may also be
difficult to evaluate in patients with severe MR because the
ejection fraction (EF) can be maintained in the presence of
LV dysfunction (5). The American College of Cardiology
and American Heart Association recommend surgery for
severe MR if symptoms occur or there is evidence of
asymptomatic LV dysfunction, defined as an LV end-
systolic dimension of 45 mm or an EF of 60% (6).
However, difficulties in detecting early LV dysfunction,
accurately assessing the severity of regurgitation, or recog-
nizing early cardiac symptoms can make it difficult to
determine the optimal timing of mitral valve surgery (7).
Brain natriuretic peptide (BNP), amino-terminal brain na-
triuretic peptide (N-BNP), and atrial natriuretic peptide
(ANP) are synthesized and secreted by cardiac myocytes in
response to increases in wall stress (8,9). Plasma levels of the
natriuretic peptides are elevated with LV systolic dysfunction
after myocardial infarction (MI) and are independent prognos-
ticators (10,11). It is possible that natriuretic peptide testing in
patients with MR will add to the information obtained from
echocardiography, but to date there are only limited published
data (12). In this study, natriuretic peptide levels were mea-
sured in patients with MR as potential markers of the severity
of regurgitation, LV dysfunction, and the presence of symp-
toms.
METHODS
Patients. Patients referred to a single cardiac center for
echocardiography between January 2000 and October 2001
who met the entry criteria for the study were invited to
participate. Forty-nine patients with isolated MR and LV
EFs of 55% on the screening echocardiogram were
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enrolled in the study. The exclusion criteria included mitral
stenosis (mitral valve area 1.5 cm2), aortic valve disease
(peak velocity across aortic valve 2.5 m/s or more than
mild aortic regurgitation), LV hypertrophy (LV wall thick-
ness 12 mm), primary right heart disease, history of MI,
previous cardiac surgery, uncontrolled hypertension (blood
pressure 160/100 mm Hg), plasma creatinine level 0.18
mmol/l, and the presence of moderate or severe respiratory
disease. One hundred normal subjects without clinical
symptoms and without signs of cardiopulmonary or renal
disease were used as controls. The study protocol was
approved by the regional ethics committees, and all patients
gave written informed consent.
Clinical assessment. Symptoms were assessed indepen-
dently by two cardiologists blinded to the natriuretic peptide
levels and echocardiographic findings. Patients were judged
symptomatic if they had a history of dyspnea on exertion
(New York Heart Association functional class 2) or
required treatment with a loop diuretic for dyspnea. The
heart rate, blood pressure, cardiac rhythm, height, weight,
and current medications were recorded. Clinical outcomes
including mitral valve surgery, death, and hospital admis-
sion for heart failure were determined for a median of 16
months following the baseline assessment.
Echocardiographic data. All patients underwent echocar-
diographic and Doppler examination using a standard
protocol on commercially available systems (Series 5 or
Vivid 5 System, GE Vingmed Ultrasound, Horten, Nor-
way). Analysis was performed at a later time by one of two
experienced echocardiographers blinded to the patients’
symptom status and natriuretic peptide levels. The LV
end-systolic and end-diastolic dimensions, LV wall thick-
ness, and left atrial (LA) dimensions were measured accord-
ing to American Society of Echocardiography guidelines
(13). All measurements were averaged from three to five
cardiac cycles. The LA volume was estimated using the
biplane ellipsoid formula. The LV end-systolic and end-
diastolic volumes and EF were measured from the apical
four-chamber view using the modified Simpson’s single-
plane method (13). Because the results of analyses were
similar when the LA and LV sizes were estimated from a
single parasternal dimension as compared with calculated
volumes, the results for dimensions only are presented. The
severity of MR was assessed from the regurgitant fraction
(14) and vena contracta width (15), and the MR score
described by Thomas et al. (2). The MR score is calculated
from visual assessment of LA size, MR jet penetration,
mitral continuous-wave Doppler characteristics, pulmonary
venous flow pattern, tricuspid regurgitation velocity, and
proximal isovelocity surface area radius.
Measurement of natriuretic peptide levels. Venous blood
samples were taken on usual medications with the patient
resting quietly while semi-recumbent. The samples were
taken into chilled ethylene-diamine-tetra-acetic acid vacu-
tainers, placed immediately on ice, and centrifuged within
20 min at 4°C. The plasma was stored at 80°C before
being assayed for BNP, N-BNP, and ANP using estab-
lished radioimmunoassays (16–18). The within-assay coef-
ficients of variation for the natriuretic peptides were 5.2%
for BNP, 3.5% for N-BNP 200 pmol/l, 3.9% for N-BNP
50 to 200 pmol/l, 11.6% for N-BNP50 pmol/l and 2% for
ANP. To convert natriuretic peptide levels expressed in
pmol/l to pg/ml, multiply by 3.47 for BNP, 8.46 for
N-BNP, and 3.08 for ANP (16–18).
Statistical analysis. The Student t test was used to com-
pare continuous variables between groups. The Fisher exact
test was used to compare categorical variables, as more than
25% of the classes had frequencies 5. Normality was
checked for each variable using box and whisker and
probability plots and the Shapiro-Wilk normality test.
Distribution of the peptides were skewed but were normal
after natural logarithmic (Ln) transformation. The Pearson
correlation coefficient was used to assess the association
between the Ln of natriuretic peptide levels and echo-
cardiographic variables. General linear models were used to
assess natriuretic peptide levels in symptomatic and asymp-
tomatic patients with adjustment for measures of the sever-
ity of MR, LV function, or age and gender (where stated).
For the ratio of the geometric means between the groups
(symptomatic/asymptomatic), 95% confidence intervals
(CIs) are reported for each peptide (19). The areas under
the receiver-operator characteristic (ROC) curves were used
to evaluate the diagnostic performance of natriuretic peptide
and echocardiographic measurements for the presence of
symptoms. A Stata 6.0 statistical software package (Stata
Corporation, College Station, Texas) was used for ROC
curve analysis and SAS release 8.0 software (SAS Institute,
Cary, North Carolina) was used for the remaining analyses.
RESULTS
Patient characteristics. Of the 49 patients with MR, 25
were men and 24 women. The mean age was 55 19 years.
There were 100 normal controls, of whom 41 were men and
59 women (mean age 55  11 years). The etiology of MR
was rheumatic in 15 patients, 4 of whom had mild mitral
stenosis (mitral valve area 1.5 cm2), mitral valve prolapse
in 33 patients, and postendocarditis in one patient. Thirty-
three patients were asymptomatic and 16 were symptomatic.
Abbreviations and Acronyms
ANP  atrial natriuretic peptide
BNP  brain natriuretic peptide
CI  confidence interval
EF  ejection fraction
LA  left atrial
Ln  natural logarithm
LV  left ventricular
MI  myocardial infarction
MR  mitral regurgitation
N-BNP  amino-terminal brain natriuretic peptide
ROC  receiver-operator characteristic
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The clinical characteristics and echocardiographic measure-
ments of asymptomatic and symptomatic patients are com-
pared in Table 1 . Symptomatic patients were more likely to
be in atrial fibrillation and to be treated with a loop diuretic
or an angiotensin-converting enzyme inhibitor. On average,
symptomatic patients had more severe MR as measured by
the regurgitant fraction, vena contracta width, and MR
score. They also had larger LA dimensions and a trend
toward larger LV end-diastolic and end-systolic dimensions
that did not reach statistical significance. The LV EFs were
similar in asymptomatic and symptomatic patients, and no
significant differences existed in age, gender, smoking,
history of hypertension, measured blood pressure, diabetes
mellitus, or serum creatinine levels.
Relation between natriuretic peptides and echocardio-
graphic measures. Correlation coefficients for the associa-
tions between each of the natriuretic peptides and echocar-
diographic measures of the severity of MR, LA dimension,
and LV size and function are presented in Table 2. The
plasma levels of BNP, N-BNP, and ANP rose with increas-
ing severity of MR and with increasing LA dimensions. The
correlation coefficients were similar for BNP, N-BNP, and
ANP. No statistically significant correlation existed between
any of the natriuretic peptides and the LV dimensions or
EF.
Natriuretic peptides in normal subjects. In normal sub-
jects the plasma levels of natriuretic peptides rose with
increasing age. For an increase in age of 10 years, BNP on
average increased 1.25 (95% CI 1.16 to 1.36) times, N-BNP
increased 1.40 (95% CI 1.25 to 1.57) times, and ANP
increased 1.30 (95% CI 1.21 to 1.38) times. Plasma levels of
natriuretic peptides were higher in women than in men after
adjustment for age (BNP 1.33 [95% CI 1.13 to 1.57] times
higher, N-BNP 1.70 [95% CI 1.33 to 2.18] times higher,
Table 1. Comparison of Asymptomatic and Symptomatic Patients With MR
Asymptomatic MR
(n  33)
Symptomatic MR
(n  16) p Value
Clinical features, number of patients
Mitral valve prolapse 23 10
Rheumatic mitral valve disease 10 5
Postendocarditis 0 1 0.34†
Loop diuretic 0 12 0.0001
ACE inhibitor 6 10 0.003
Atrial fibrillation 2 6 0.01
Echocardiography, mean  SD
Regurgitant fraction (%) 40  14 56  16 0.001
Vena contracta width (mm) 3.5  1.0 4.7  0.9 0.0002
MR score 1.4  0.5 2.2  0.4 0.0001
LA dimension (cm) 4.2  0.6 5.1  0.8 0.0001
RV systolic pressure (mm Hg)* 22  7 32  12 0.013
LV wall thickness (cm) 0.97  0.13 0.96  0.20 0.90
LV end-systolic dimension (cm) 3.1  0.4 3.5  0.8 0.15
LV end-diastolic dimension (cm) 5.3  0.6 5.7  1.0 0.18
LV systolic wall stress (g/cm2) 162  33 147  21 0.09
EF (%) 63  5 63  6 0.99
*The RV systolic pressure could be estimated from the tricuspid regurgitant jet velocity in 14 asymptomatic and 13 symptomatic
patients. †Chi-squared test used to calculate p value.
ACE  angiotensin-converting enzyme; EF  ejection fraction; LA  left atrial; LV  left ventricular; MR  mitral
regurgitation; RV  right ventricular.
Table 2. Correlation Among Natriuretic Peptide Levels, Age, Body Surface Area, and
Echocardiographic Measures of the Severity of MR and LV Function
Ln N-BNP r (p) Ln BNP r (p) Ln ANP r (p)
Age 0.50 (0.0003) 0.46 (0.0009) 0.38 (0.006)
Body surface area 0.31 (0.03) 0.33 (0.02) 0.17 (0.23)
Regurgitant fraction 0.41 (0.003) 0.43 (0.002) 0.40 (0.005)
Vena contracta width 0.54 (0.0001) 0.60 (0.0001) 0.37 (0.009)
MR score 0.51 (0.0002) 0.55 (0.0001) 0.49 (0.0003)
LA dimension 0.66 (0.0001) 0.65 (0.0001) 0.49 (0.0004)
RV systolic pressure* 0.33 (0.09) 0.42 (0.03) 0.47 (0.01)
LV posterior wall thickness 0.15 (0.30) 0.13 (0.36) 0.03 (0.86)
LV end-systolic dimension 0.16 (0.27) 0.20 (0.16) 0.16 (0.26)
LV end-diastolic dimension 0.17 (0.26) 0.19 (0.20) 0.13 (0.37)
LV systolic wall stress 0.11 (0.45) 0.02 (0.88) 0.01 (0.95)
EF 0.01 (0.92) 0.003 (0.98) 0.20 (0.17)
*n  27.
ANP atrial natriuretic peptide; BNP brain natriuretic peptide; Ln natural logarithm; N-BNP amino-terminal brain
natriuretic peptide; r  correlation coefficient; p  p value. Other abbreviations as in Table 1.
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and ANP 1.31 [95% CI 1.13 to 1.50] times higher, p 
0.001 for all). No statistically significant interaction existed
between age and gender.
Comparison of asymptomatic and symptomatic patients.
Table 3 shows the natriuretic peptide levels of the symp-
tomatic and asymptomatic patients with MR and the
control subjects. After adjustment for age, gender, and body
surface area, the levels of each of the natriuretic peptides
were on average higher in asymptomatic patients with MR
than in normal controls (p  0.001 for all), and higher in
symptomatic than in asymptomatic patients with MR (p 
0.001 for all). The differences between symptomatic and
asymptomatic patients with MR remained after adjustment
was also made for the LV end-systolic dimension (BNP
2.06 [95% CI 1.32 to 3.23] times higher, N-BNP 2.63 [95%
CI 1.46 to 4.75] times higher, and ANP 2.11 [95% CI 1.38
to 3.21] times higher), LA dimension (BNP 1.45 [95% CI
0.95 to 2.22] times higher, N-BNP 1.57 [95% CI 1.09 to
2.70] times higher, and ANP 1.79 [95% CI 1.15 to 2.81]
times higher), MR score (BNP 1.9 [95% CI 1.1 to 3.1]
times higher, N-BNP 2.5 [95% CI 1.3 to 4.9] times higher,
and ANP 1.8 [95% CI 1.1 to 2.9] times higher), and vena
contracta width (BNP 1.5 [95% CI 1.0 to 2.4] times higher,
N-BNP 2.0 [95% CI 1.1 to 3.7] times higher, and ANP 2.1
[95% CI 1.3 to 3.3] times higher). The associations between
BNP and the LV end-systolic dimension, vena contracta
width, and LA dimension in asymptomatic and symptom-
atic patients are shown in Figure 1.
The sensitivity, specificity, and area under the ROC curve
for symptoms by natriuretic peptide levels and echocardio-
graphic measures are shown in Table 4. An ROC curve
showing the sensitivity and specificity of BNP, LA dimension,
vena contracta width, and LV end-systolic dimension for the
presence of symptoms is depicted in Figure 2 . The area under
the ROC curve was higher for each of the natriuretic peptides
than for the echocardiographic measures of the severity of
regurgitation, LA size, and LV dimensions.
Clinical outcomes. After a median follow-up of 16 (range
6.2 to 23) months, seven (44%) symptomatic patients had
mitral valve surgery (BNP values at baseline: 11 pmol/l, 12
pmol/l, 21 pmol/l, 22 pmol/l, 23 pmol/l, 33 pmol/l, and 52
pmol/l). One symptomatic patient had a normal exercise
stress echocardiogram and was not referred for surgery
(BNP 12 pmol/l). The other eight symptomatic patients
declined surgery or were not referred because of co-
morbidity; two died from noncardiac causes. Four (12%)
asymptomatic patients underwent mitral valve surgery; in
three there was no clinical or echocardiographic change
before surgery performed for a flail leaflet (n  2, BNP 6
pmol/l and 7 pmol/l, respectively) or coexistent coronary
artery disease (n  1, BNP 7 pmol/l). One asymptomatic
patient developed worsening LV function and symptoms
and was referred for surgery after 20 months’ follow-up
(BNP 4 pmol/l). Serial measurements of natriuretic peptides
were not obtained during follow-up.
Table 3. Clinical Characteristics and Plasma Natriuretic Peptide Levels in Normal Controls and
in Asymptomatic and Symptomatic Patients With MR
Normal Controls
(n  100)
Asymptomatic MR
(n  33)
Symptomatic MR
(n  16)
Male gender (%) 41 (41) 19 (58) 6 (37)
Age (yrs) 55  11 52  18 59  20
Body surface area (m2) 1.8  0.20 1.9  0.18 1.8  0.28
BNP (pmol/l)* 5.3 (4.8–5.8) 7.1 (6.0–8.4)† 16.9 (13.3–21.4)‡
N-BNP (pmol/l)* 12.3 (10.8–14.0) 28.3 (22.5–35.6)§ 85.4 (61.3–119.0)‡
ANP (pmol/l)* 9.3 (8.5–10.1) 12.4 (10.7–14.4)† 24.1 (19.5–29.9)‡
*Geometric mean (95% confidence interval) adjusted for age, gender, and body surface area. †p  0.003 for comparison with
normal controls. ‡p  0.0001 for comparison with patients with asymptomatic MR. §p  0.0001 for comparison with normal
controls.
Abbreviations as in Tables 1 and 2.
Table 4. Sensitivity and Specificity of Natriuretic Peptide Levels and Echocardiographic
Parameters for Symptoms in Patients With MR
Variable Cut Point Sensitivity (%) Specificity (%) AUC
BNP (pmol/l) 12* 75 85 0.90
N-BNP (pmol/l) 50* 88 79 0.89
ANP (pmol/l) 19* 81 79 0.89
LA dimension (cm) 4 88 30 0.81
MR score 2 63 91 0.88
Vena contracta width (mm) 4 75 70 0.82
Regurgitant fraction (%) 50 69 85 0.78
LV end-systolic dimension (cm) 4.5 13 100 0.63
LV end-diastolic dimension (cm) 6 31 88 0.62
EF (%) 60 31 76 0.54
*Upper limit of normal range for laboratory.
AUC  area under receiver-operator characteristic curve. Other abbreviations as in Tables 1 and 2.
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Figure 1. Association between plasma brain natriuretic peptide (BNP) levels and (A) vena contracta width, (B) left ventricular end-systolic dimension, and
(C) left atrial dimension in asymptomatic (open circles) and symptomatic (closed circles) patients with mitral regurgitation. The dashed lines indicate the
upper limit of the normal laboratory reference range for BNP. Continued on next page.
2284 Sutton et al. JACC Vol. 41, No. 12, 2003
Natriuretic Peptides in MR June 18, 2003:2280–7
DISCUSSION
Obtaining an accurate quantitative assessment of the sever-
ity of MR is technically demanding (2–4). For this reason a
qualitative assessment of severity based on several echocar-
diographic measures is often used in clinical practice. In this
study the natriuretic peptides BNP, N-BNP, and ANP
increased with increasing MR assessed by three echocardio-
graphic measures, the width of the vena contracta (15), the
regurgitant fraction (14), and the MR score (2). Conversely,
no statistically significant correlation existed between the
LV end-systolic dimension, LV end-diastolic dimension or
EF, and natriuretic peptide levels. The echocardiographic
measure most strongly associated with both natriuretic
peptide levels and the presence of symptoms was the LA
dimension.
In addition to associations with echocardiographic mea-
sures of the severity of MR, natriuretic peptide levels were
higher in symptomatic than in asymptomatic patients.
Symptomatic patients were more likely to have more severe
MR, but the association between natriuretic peptide levels
and symptoms remained statistically significant, although
weaker, after adjustment for echocardiographic measures of
the severity of regurgitation and LV function. These obser-
vations suggest that natriuretic peptide levels provide an
additional method for assessing the severity and symptoms
of MR when the LV EF is normal.
Few published studies have evaluated natriuretic peptide
levels in MR, Brookes et al. (12) measured BNP levels in 22
patients with MR, but that study included patients with
impaired LV function and did not assess the relation
between the severity of MR and natriuretic peptide levels.
As in the current study, BNP levels were higher in symp-
tomatic patients, and no significant association was seen
between BNP levels and LV dimensions.
In the current study the increase in plasma N-BNP levels
seen with increasing severity of MR and with increasing
symptoms was greater than for BNP, but the strength of the
association was similar. The N-terminal fragment of BNP
does not have specific clearance receptors and, therefore, has
a longer half-life and a higher plasma concentration than
BNP (20). Previous studies suggest that BNP is primarily
synthesized by ventricular myocytes and reflects changes in
ventricular function, whereas ANP is predominantly stored
in atrial myocytes and released in response to increases in
atrial wall “stress” (8,21). In the current study, natriuretic
peptide secretion in patients with MR appeared to be
related to increases in LA rather than LV wall “stress.” The
relative increases in the plasma levels of BNP and N-BNP
were as large as for ANP, and the correlations with the LA
dimension, severity of MR, and symptoms were similar for
the three peptides. A possible explanation is that atrial
myocytes synthesize BNP as well as ANP in response to the
chronic increase in LA pressure. This hypothesis is sup-
ported by the demonstration of synthesis of BNP by atrial
cardiomyocytes and co-storage of ANP and BNP in atrial
granules (22,23).
Figure 1 Continued.
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Results of this study suggest that natriuretic peptide
testing may add to the information obtained by echocardi-
ography in the assessment of MR in clinical practice. When
echocardiographic assessment is technically difficult, low
N-BNP, BNP, or ANP levels would suggest that MR is not
severe. Measurement of natriuretic peptides may also be
useful when it is not clear whether symptoms of dyspnea or
fatigue are due to cardiac disease (24,25). Prospective
follow-up studies are needed to determine whether natri-
uretic peptides can be used to monitor asymptomatic pa-
tients with moderate to severe MR in the primary care
setting, or to guide timing of surgery. Limited clinical
follow-up in the current study suggests a single baseline
measurement does not reliably predict disease progression,
but serial measurements may be useful.
Study limitations. In normal subjects, natriuretic peptides
increased with age, were higher in women than in men, and
were inversely related to body surface area, as observed in
other studies (26). Patients with MR were compared with
the normal subjects, but further studies are needed to
determine whether and how the impact of age, gender, and
body surface area on natriuretic peptide levels should influ-
ence the interpretation of plasma levels. To allow assess-
ment of the effects of MR on natriuretic peptide levels,
patients with other causes of elevated plasma natriuretic
peptides were excluded from this study. Further investiga-
tions are needed to determine whether the association
between natriuretic peptide levels and symptoms is similar
in persons with additional cardiac conditions that are known
to increase natriuretic peptide levels. As in clinical practice,
assessment of symptoms may be difficult. It is likely that in
some patients the symptoms were not a consequence of
MR, while others were classified as asymptomatic because
they undertook little activity or ignored subtle symptoms.
Previous studies have demonstrated a clear inverse relation-
ship between the LV EF and BNP and N-BNP levels after
MI or with cardiac failure (9–11). In the current study, no
clear association was seen between natriuretic peptide levels
and the EF, but patients with an EF of 55% on the
screening echocardiogram were excluded. Additional stud-
ies are needed to confirm that natriuretic peptide levels
increase further when LV function declines in patients with
MR. Another consideration is the possible presence of LV
dysfunction when the EF is maintained in MR. Additional
investigations not performed in the current study, such as
exercise stress echocardiography, can identify LV dysfunc-
tion with a maintained resting EF, and these may improve
the assessment of symptoms in some patients (27).
Conclusions. Plasma levels of BNP, N-BNP, and ANP
rise with increasing severity of MR and are higher in
symptomatic than in asymptomatic patients, even after
adjustment for echocardiographic measures of the severity
of regurgitation. Prospective follow-up studies are needed to
determine whether natriuretic peptides will provide a simple
low-cost method for monitoring asymptomatic patients and
whether repeated measurements are useful for deciding on
timing of surgery.
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